Cytotoxic payloads for antibody-drug conjugates

Introduction to Antibody-Drug Conjugates (ADCs)
 Design Factors Important for Antibody-Drug Conjugate (ADC) Payloads
 Use of Molecular Modelling Techniques in Antibody-Drug Conjugate (ADC) Payload Discovery and Development
 Auristatin Payloads for Antibody-Drug Conjugates (ADCs)
 Maytansinoid Payloads for Antibody-Drug Conjugates (ADCs)
 Colchicine-, Vinblastine-, Taxol- and Eribulin-based Payloads for Antibody-Drug Conjugates (ADCs)
 Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads
 Topoisomerase Inhibitors as Antibody-Drug Conjugate (ADC) Payloads
 Duocarmycins as Antibody-Drug Conjugate (ADC) Payloads
 CXI Dimers as Antibody-Drug Conjugate (ADC) Payloads
 Duocarmycin-PBD Dimers as Antibody-Drug Conjugate (ADC) Payloads
 Calicheamicins as Antibody-Drug Conjugate (ADC) Payloads
 Pro-pyrrolobenzodiazepines and Conjugates as Antibody-Drug Conjugate (ADC) Payloads
 Pyrrolobenzodiazepine Dimers as Antibody-Drug Conjugate (ADC) Payloads
 Indolinobenzodiazepine Dimers (IGNs) as Antibody-Drug Conjugate (ADC) Payloads
 Pyridinobenzodiazepines (PDDs) as Sequence-selective DNA Mono-alkylating Antibody-Drug Conjugate (ADC) Payloads
 Splicing Inhibitors as Antibody-Drug Conjugate (ADC) Payloads
 Tubulysins as Antibody-Drug Conjugate (ADC) Payloads
 Amatoxins as RNA Polymerase II Inhibiting Antibody-Drug Conjugate (ADC) Payloads
 Protein Toxins as Antibody-Drug Conjugate (ADC) Payloads
 Occupational Health and Safety Considerations for the Handling and Manufacture of Antibody-Drug Conjugate (ADC) Payloads
 The Future of Antibody-Drug Conjugate (ADC) Payloads